News & Updates
Filter by Specialty:
FASN inhibitor for MASH with fibrosis gets a pass to phase III
The oral fatty acid synthase (FASN) inhibitor denifanstat appears to produce meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2–3 fibrosis, as shown in the results of a phase IIb trial.
FASN inhibitor for MASH with fibrosis gets a pass to phase III
28 Oct 2024
Survodutide safe to use in cirrhosis patients
Treatment with survodutide, which has previously shown its efficacy in reducing body weight and glycaemia in people with obesity or type 2 diabetes, is well tolerated by patients with compensated or decompensated cirrhosis, reports a study.
Survodutide safe to use in cirrhosis patients
27 Oct 2024
IV iron replacement safe, effective for anemia after variceal bleed in cirrhosis patients
Patients with cirrhosis with iron deficiency anemia after variceal bleed (VB) can rely on the efficacy and safety of intravenous (IV) iron replacement, reports a study.
IV iron replacement safe, effective for anemia after variceal bleed in cirrhosis patients
21 Oct 2024
New model predicts HCC risk in noncirrhotic CHB patients
A novel prognostic model based on the viral loads of hepatitis B virus (HBV) demonstrates its utility in predicting and stratifying the risk of hepatocellular carcinoma (HCC) in noncirrhotic patients with chronic hepatitis B (CHB) who are not yet receiving antiviral therapy.
New model predicts HCC risk in noncirrhotic CHB patients
07 Oct 2024
Long-term bulevirtide use safe, efficacious in chronic HDV
Longer treatment with bulevirtide (BLV) monotherapy in patients with chronic hepatitis delta (CHD) for 96 weeks results in sustained or continued improvements in virologic, biochemical, and combined responses, a study has shown.